International Journal of Cardiology, Год журнала: 2024, Номер unknown, С. 132944 - 132944
Опубликована: Дек. 1, 2024
Язык: Английский
International Journal of Cardiology, Год журнала: 2024, Номер unknown, С. 132944 - 132944
Опубликована: Дек. 1, 2024
Язык: Английский
JACC Heart Failure, Год журнала: 2025, Номер 13(4), С. 537 - 553
Опубликована: Апрель 1, 2025
Heart failure with improved ejection fraction (HFimpEF) is defined by left ventricular (LVEF) among patients who previously had reduced LVEF. HFimpEF associated prognosis, albeit persistent risk of relapse and adverse events in some patients. Current guidelines thus recommend sustained indefinite guideline-directed medical therapy (GDMT) for all HFimpEF. Emerging clinical experience suggests that heart arising from acute etiologies fully resolve along complete LVEF recovery may have a favorable prognosis lower relapse. Indeed, cohort case series studies demonstrated the feasibility safe de-escalation GDMT select specific etiologies, multiple small trials ongoing. Future should investigate whether advanced imaging or blood biomarkers could aid stratifying recovered LVEF, partial be feasible, implantable cardioverter-defibrillator can safely discontinued.
Язык: Английский
Процитировано
2International Journal of Cardiology, Год журнала: 2024, Номер unknown, С. 132944 - 132944
Опубликована: Дек. 1, 2024
Язык: Английский
Процитировано
0